Delineating common molecular mechanisms in Alzheimer's and prion diseases.
about
Studies of the transmissibility of the agent of bovine spongiform encephalopathy to the domestic chickenTowards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesBrain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid systemE2-25K/Hip-2 regulates caspase-12 in ER stress-mediated Abeta neurotoxicityGenetic cross-interaction between APOE and PRNP in sporadic Alzheimer's and Creutzfeldt-Jakob diseases.A drastic reduction in the life span of cystatin C L68Q carriers due to life-style changes during the last two centuries.Linking amyloid protein aggregation and yeast survival.Redox control of prion and disease pathogenesis.Conservation of a glycine-rich region in the prion protein is required for uptake of prion infectivityTDP-43 is directed to stress granules by sorbitol, a novel physiological osmotic and oxidative stressor.Cellular prion protein expression is not regulated by the Alzheimer's amyloid precursor protein intracellular domain.Medulla oblongata transcriptome changes during presymptomatic natural scrapie and their association with prion-related lesions.A common BACE1 polymorphism is a risk factor for sporadic Creutzfeldt-Jakob diseaseChemistry and biology of mammalian metallothioneins.Structural and mechanistic commonalities of amyloid-β and the prion proteinHelices 2 and 3 are the initiation sites in the PrP(C) → PrP(SC) transitionGenetic variability of the gene cluster CALHM 1-3 in sporadic Creutzfeldt-Jakob disease.Neurotoxic species in prion disease: a role for PrP isoforms?Dietary magnesium and copper affect survival time and neuroinflammation in chronic wasting diseaseDesign of anti- and pro-aggregation variants to assess the effects of methionine oxidation in human prion protein.Therapeutic interventions ameliorating prion disease.Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders.Metal attenuating therapies in neurodegenerative disease.A review of metal-catalyzed molecular damage: protection by melatonin.The role of ubiquitin-binding domains in human pathophysiology.Proteomic Analyses for the Global S-Nitrosylated Proteins in the Brain Tissues of Different Human Prion Diseases.Antioxidant and Metal Chelation-Based Therapies in the Treatment of Prion Disease.Amyloid-β Activates Microglia and Regulates Protein Expression in a Manner Similar to Prions.Regulation of prion gene expression by transcription factors SP1 and metal transcription factor-1.The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor.Regulation of adenosine triphosphate-sensitive potassium channels suppresses the toxic effects of amyloid-beta peptide (25-35)Increased proportions of C1 truncated prion protein protect against cellular M1000 prion infection.Electrospray ionization mass spectrometric approach of conformationally-induced metal binding to oligopeptides.Manganese chelation therapy extends survival in a mouse model of M1000 prion disease.Do prion protein gene polymorphisms induce apoptosis in non-mammals?Rat's trick to escape Alzheimer's disease.
P2860
Q21199593-720C4461-26FA-48D6-87A7-3E2B04B29DDFQ24289511-2C542CB7-1F2B-4972-98FF-AA95E6F63550Q26865295-DB229131-4F5D-46EE-8AB5-1647F5FFFCB4Q28508974-8277499D-5070-45CC-9280-99A4CA3552CBQ31026808-A3CA9A0F-DCD3-44D7-A298-2EDD7B7DD883Q33345227-4AF5452A-86BD-4AC3-BC38-B5A234A2C7B1Q33794914-14B6FCFE-E2F1-46B9-931A-B749AEEB7080Q33830151-8BF75EC9-076C-4B69-9F55-6B729A3B8B21Q33924421-E6F6C462-1EAF-4EA6-971D-11C98E82E6F9Q34155890-A8703573-1100-411A-8E54-4D1F3A239AFAQ34171325-6BD79D7B-3DA0-4D94-85E9-0632D6B1C039Q34381751-93627145-6BDA-4F9E-87F3-CB79ACE497D1Q34405864-2014C12E-4585-440F-997C-42CE10910CC6Q34629949-3B2C07C3-2292-487C-B8EB-BAA0CE68E3EFQ35578753-A3E347AD-D9D5-40CF-B81D-E6D26F3F8F3BQ36598840-BD9AFB66-7C4C-4819-9AE8-4FEE511B5E72Q36719069-561E5281-4462-444D-8A91-A68A6E30E741Q36974937-F9FC4A3E-D12D-4F9F-A286-FEFBCE58FA46Q37167882-A26B297B-EFEA-47C2-AB9F-3AB5C2D61FECQ37172413-7E209DE8-EC65-4996-B554-36A54B19952CQ37557690-E6EA0ACF-9480-4652-84B9-AB2F5AD9D52AQ37825636-B5C56D6B-EB40-4245-BE0C-D0AA664354DFQ37957126-CB5A4685-214D-42D2-AF44-BC2424DCA293Q38195865-E07EACDB-DDD9-4DCF-AD72-33B24E667369Q38217924-D06F677C-40FE-4098-90AD-2A4CCDD342A9Q38403381-57050479-93A4-4FBB-B210-C5A7BC4B334FQ38702726-DF01BBB3-D2E4-4D05-8C6D-98F1D4D02529Q38887770-BFA3707A-1B98-4A2C-AFA2-59484FF906DBQ39920234-8DFF7737-2C1E-4CB7-825E-37026D4F58FEQ40173639-A28450EE-933D-4EE1-8DE0-252099C67F4BQ42744312-D23E038C-3FF4-43B4-A906-1AACEEB0B6DFQ42832124-E942C51B-01B6-4B97-9889-A110E8705A1FQ42972356-2DB94DED-5B2C-494E-927B-30F6147E7A41Q43067894-93FDD3C5-3FB9-48EE-900D-688729C86123Q46584144-B134A854-9BE1-4963-B4D1-18FD27EC2AA5Q50888807-67D56DCC-FDFF-42B9-9296-35CFF36FD8DE
P2860
Delineating common molecular mechanisms in Alzheimer's and prion diseases.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Delineating common molecular mechanisms in Alzheimer's and prion diseases.
@ast
Delineating common molecular mechanisms in Alzheimer's and prion diseases.
@en
type
label
Delineating common molecular mechanisms in Alzheimer's and prion diseases.
@ast
Delineating common molecular mechanisms in Alzheimer's and prion diseases.
@en
prefLabel
Delineating common molecular mechanisms in Alzheimer's and prion diseases.
@ast
Delineating common molecular mechanisms in Alzheimer's and prion diseases.
@en
P2093
P1476
Delineating common molecular mechanisms in Alzheimer's and prion diseases.
@en
P2093
Andrew F Hill
Kevin J Barnham
Roberto Cappai
P304
P356
10.1016/J.TIBS.2006.06.006
P577
2006-07-03T00:00:00Z